Table 1.
Clinicopathological characteristics of the patients
| Nivolumab (n = 40) | Pembrolizumab (n = 21) | |
|---|---|---|
| Median age, years (range) | 70 (44–81) | 69 (48–82) |
| Sex | ||
| Male / Female | 34/6 | 20/1 |
| Brinkman index | ||
| ≧400/<400 | 35/5 | 18/3 |
| Histology | ||
| Squamous/Nonsquamous | 16/24 | 6/15 |
| Stage | ||
| up to III/IV/recurrence | 11/20/9 | 7/10/4 |
| ECOG PS | ||
| 0 / 1 / 2+ | 14/18/8 | 7/11/3 |
| PD‐L1 expression (%) | ||
| 0 / 1–49/50 + / n.d. | 12/14/5/9 | 0/3/18/0 |
| Treatment line | ||
| 1/2+ | 0/40 | 14/7 |
| Preexisting IIP or radiation pneumonitis | ||
| Y/N | 6/34 | 6/15 |
ECOG, Eastern Cooperative Oncology Group; IIP, idiopathic interstitial pneumonia; n.d., not determined; PD‐L1, programmed death‐ligand 1; PS, performance status;